Table 5.
Prognostic factors analysis in HR + /HER2 + breast cancer
| Factors | N | Events (%) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| X2 | P-value | HR (95% CI) | P-value | |||
| All patients | 429 | 23(5.4) | ||||
| Age | 0.045 | 0.832 | ||||
| < 50 | 233 | 12(5.2) | ||||
| ≥ 50 | 196 | 11(5.6) | ||||
| Menstrual status | 0.086 | 0.769 | ||||
| Premenopausal | 255 | 13(5.1) | ||||
| Postmenopausal | 174 | 10(5.7) | ||||
| T stage | 4.211 | 0.04 | ||||
| T1, T2 | 335 | 14(4.2) | ref | |||
| T3, T4 | 94 | 9(9.6) | 1.994(1.148–3.264) | 0.047 | ||
| N stage | 3.873 | 0.049 | ||||
| N0 | 131 | 3(2.3) | ref | |||
| N + | 298 | 20(6.7) | 2.970(1.364–5.907) | 0.026 | ||
| Histological type | 0.301 | 0.583 | ||||
| IDC | 355 | 20(5.6) | ||||
| Others | 74 | 3(4.1) | ||||
| Histological grade | 3.12 | 0.077 | ||||
| I, II | 244 | 9(3.7) | ||||
| III | 185 | 14(7.6) | ||||
| ki67 index | 2.274 | 0.132 | ||||
| < 14% | 66 | 1(1.5) | ||||
| ≥ 14% | 363 | 22(6.1) | ||||
| P53 status | 5.576 | 0.016 | ||||
| Negative | 252 | 8(3.2) | ref | |||
| Positive | 177 | 15(8.5) | 1.475(0.549–2.752) | 0.139 | ||
| HER2 status | 0.496 | 0.481 | ||||
| 2 + /FISH + | 99 | 9(9.1) | ||||
| 3 + | 116 | 14(12.1) | ||||
| AR status | 10.11 | 0.002 | ||||
| Negative | 56 | 8(14.3) | ref | |||
| Positive | 373 | 15(4.0) | 0.803(0.167–0.959) | 0.012 | ||
| EGFR status | 0.219 | 0.64 | ||||
| Negative | 279 | 16(5.7) | ||||
| Positive | 150 | 7(4.7) | ||||
| CK5/6 status | 0.106 | 0.745 | ||||
| Negative | 373 | 20(5.4) | ||||
| Positive | 56 | 3(5.4) | ||||
| Surgery | 0.29 | 0.59 | ||||
| Conservative | 94 | 4(4.3) | ||||
| Mastectomy | 335 | 19(5.7) | ||||
| Radiotherapy | 0.022 | 0.882 | ||||
| Yes | 341 | 18(5.3) | ||||
| No | 88 | 5(5.7) | ||||
| NAC effect | 1.778 | 0.182 | ||||
| pCR | 106 | 3(2.8) | ||||
| non-pCR | 323 | 20(6.2) | ||||
IDC invasive ductal carcinoma, NAC neoadjuvant chemotherapy